207 related articles for article (PubMed ID: 37030416)
1. Vitamin K2 enhances the tumor suppressive effects of 1,25(OH)
Narvaez CJ; Bak MJ; Salman N; Welsh J
J Steroid Biochem Mol Biol; 2023 Jul; 231():106307. PubMed ID: 37030416
[TBL] [Abstract][Full Text] [Related]
2. Divergent effects of vitamins K1 and K2 on triple negative breast cancer cells.
Beaudin S; Kokabee L; Welsh J
Oncotarget; 2019 Mar; 10(23):2292-2305. PubMed ID: 31040920
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of 1,25-dihydroxyvitamin D3 and tetradecanoylphorbol acetate on cell cycle and apoptosis of MCF-7 cells and a vitamin D3-resistant variant.
Narvaez CJ; Welsh J
Endocrinology; 1997 Nov; 138(11):4690-8. PubMed ID: 9348195
[TBL] [Abstract][Full Text] [Related]
4. Vitamin K2 promotes 1alpha,25(OH)2 vitamin D3-induced mineralization in human periosteal osteoblasts.
Koshihara Y; Hoshi K; Ishibashi H; Shiraki M
Calcif Tissue Int; 1996 Dec; 59(6):466-73. PubMed ID: 8939773
[TBL] [Abstract][Full Text] [Related]
5. 1,25-dihydroxyvitamin D3 and retonic acid analogues induce differentiation in breast cancer cells with function- and cell-specific additive effects.
Wang Q; Lee D; Sysounthone V; Chandraratna RAS ; Christakos S; Korah R; Wieder R
Breast Cancer Res Treat; 2001 May; 67(2):157-68. PubMed ID: 11519864
[TBL] [Abstract][Full Text] [Related]
6. 20-epi-vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines.
Elstner E; Linker-Israeli M; Said J; Umiel T; de Vos S; Shintaku IP; Heber D; Binderup L; Uskokovic M; Koeffler HP
Cancer Res; 1995 Jul; 55(13):2822-30. PubMed ID: 7796409
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer.
Thakkar A; Wang B; Picon-Ruiz M; Buchwald P; Ince TA
Breast Cancer Res Treat; 2016 May; 157(1):77-90. PubMed ID: 27120467
[TBL] [Abstract][Full Text] [Related]
8. 1,25-Dihydroxyvitamin D
Li M; Li L; Zhang L; Hu W; Shen J; Xiao Z; Wu X; Chan FL; Cho CH
Life Sci; 2017 Jun; 179():88-97. PubMed ID: 28465245
[TBL] [Abstract][Full Text] [Related]
9. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
Skowronski RJ; Peehl DM; Feldman D
Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
[TBL] [Abstract][Full Text] [Related]
10. 1,25-Dihydroxyvitamin D3 promotes vitamin K2 metabolism in human osteoblasts.
Miyake N; Hoshi K; Sano Y; Kikuchi K; Tadano K; Koshihara Y
Osteoporos Int; 2001; 12(8):680-7. PubMed ID: 11580082
[TBL] [Abstract][Full Text] [Related]
11. The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression.
Campbell MJ; Gombart AF; Kwok SH; Park S; Koeffler HP
Oncogene; 2000 Oct; 19(44):5091-7. PubMed ID: 11042697
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D regulation of HAS2, hyaluronan synthesis and metabolism in triple negative breast cancer cells.
Narvaez CJ; Grebenc D; Balinth S; Welsh JE
J Steroid Biochem Mol Biol; 2020 Jul; 201():105688. PubMed ID: 32360595
[TBL] [Abstract][Full Text] [Related]
13. Dissociation of vitamin D3 and anti-estrogen mediated growth regulation in MCF-7 breast cancer cells.
Nolan E; Donepudi M; VanWeelden K; Flanagan L; Welsh J
Mol Cell Biochem; 1998 Nov; 188(1-2):13-20. PubMed ID: 9823006
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a vitamin D3-resistant MCF-7 cell line.
Narvaez CJ; Vanweelden K; Byrne I; Welsh J
Endocrinology; 1996 Feb; 137(2):400-9. PubMed ID: 8593782
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D receptor expression and associated gene signature in tumour stromal fibroblasts predict clinical outcome in colorectal cancer.
Ferrer-Mayorga G; Gómez-López G; Barbáchano A; Fernández-Barral A; Peña C; Pisano DG; Cantero R; Rojo F; Muñoz A; Larriba MJ
Gut; 2017 Aug; 66(8):1449-1462. PubMed ID: 27053631
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D and systemic cancer: is this relevant to malignant melanoma?
Osborne JE; Hutchinson PE
Br J Dermatol; 2002 Aug; 147(2):197-213. PubMed ID: 12174089
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor binding protein-5 interacts with the vitamin D receptor and modulates the vitamin D response in osteoblasts.
Schedlich LJ; Muthukaruppan A; O'Han MK; Baxter RC
Mol Endocrinol; 2007 Oct; 21(10):2378-90. PubMed ID: 17595320
[TBL] [Abstract][Full Text] [Related]
19. 1,25-Dihydroxyvitamin D3 induces differentiation of a retinoic acid-resistant acute promyelocytic leukemia cell line (UF-1) associated with expression of p21(WAF1/CIP1) and p27(KIP1).
Muto A; Kizaki M; Yamato K; Kawai Y; Kamata-Matsushita M; Ueno H; Ohguchi M; Nishihara T; Koeffler HP; Ikeda Y
Blood; 1999 Apr; 93(7):2225-33. PubMed ID: 10090931
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D compounds inhibit cancer stem-like cells and induce differentiation in triple negative breast cancer.
Shan NL; Wahler J; Lee HJ; Bak MJ; Gupta SD; Maehr H; Suh N
J Steroid Biochem Mol Biol; 2017 Oct; 173():122-129. PubMed ID: 27923595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
